Vertex Pharmaceuticals Incorporated (BIT:1VRTX)
Italy · Delayed Price · Currency is EUR | Market Cap | 101.24B -13.0% |
| Revenue (ttm) | 10.22B +8.9% |
| Net Income | 3.37B |
| EPS | 13.05 |
| Shares Out | n/a |
| PE Ratio | 30.07 |
| Forward PE | 23.94 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6 |
| Average Volume | 6 |
| Open | 403.80 |
| Previous Close | 407.70 |
| Day's Range | 401.90 - 403.80 |
| 52-Week Range | 316.00 - 482.10 |
| Beta | n/a |
| RSI | 48.87 |
| Earnings Date | Feb 12, 2026 |
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMK... [Read more]
News
Vertex to Participate in Upcoming March Investor Conferences
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. Charlie Wagner, Chief Operating and Financial...
Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from a Phase 4 study of JOURNAVX® (suzetrigine), a prescription non-opioid pain signal inhibitor for th...
Vertex Pharmaceuticals Incorporated (VRTX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Vertex Pharmaceuticals Incorporated (VRTX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
10 Best CEFs This Month: Average Yield Of 9.7% (February 2026)
The article presents a rigorously screened list of 10 top closed-end funds, or CEFs, for income investors, offering an average 9.7% yield and -10% NAV discount. Selections emphasize sector diversifica...
Vertex Pharmaceuticals Stock: Is The Bull Run Over (Rating Downgrade)
I believe Vertex Pharmaceuticals Incorporated's bull run has come to an end. There's a divergence between its stock price growth over the past 5 months and the performance of Journavx and the cystic f...
Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in TD Cowen's 46th Annual Health Care Conference. Reshma Kewalramani, President and...
Vertex Pharmaceuticals Incorporated (VRTX) Q4 2025 Earnings Call Transcript
Vertex Pharmaceuticals Incorporated (VRTX) Q4 2025 Earnings Call Transcript
Vertex Pharma forecasts 2026 revenue in-line, expects growth in cystic fibrosis treatments
Vertex Pharmaceuticals forecast 2026 revenue largely in line with analysts estimates on Thursday, as the drugmaker bets on growth for its cystic fibrosis treatments as well as contributions from newer...
Vertex Reports Fourth Quarter and Full Year 2025 Financial Results
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2025, and provided its...
Vertex Q4 Earnings Preview: What To Expect This Week
Vertex Pharmaceuticals is downgraded to Hold ahead of Q4 earnings due to underwhelming growth from key new drugs. Journavx and Casgevy sales remain niche, raising doubts about their ability to drive t...
WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager
SHANGHAI, Feb. 2, 2026 /PRNewswire/ -- WuXi Biologics (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has signed a license ...
Final Trades: Vertex Pharma, Kimberly-Clark, S&P Global and Exxon Mobil
The Investment Committee give you their top stocks to watch for the second half.
Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2025 financial results on Thursday, February 12, 2026, after the financial mark...
Vertex Pharmaceuticals Incorporated (VRTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Vertex Pharmaceuticals Incorporated (VRTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced business and program updates ahead of upcoming investor meetings in January, including the company's schedul...
Vertex Pharmaceuticals: Prepared To Defend Their Dominance And Expand Their Expertise
Vertex Pharmaceuticals remains a 'Top Idea' with robust Q3 earnings, a dominant CF franchise, and a broadening late-stage pipeline. VRTX's diversification into pain, kidney, cell, and gene therapies p...
Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 44th Annual J.P. Mor...
Best Defensive Stocks To Balance Tech Sector Volatility
December's mixed performance for tech may be an early signal that leadership is narrowing, especially among the value-stretched stocks. Investors looking forward to 2026 may find better risk-adjusted ...
Harbor Capital Appreciation Fund Q3 2025 Portfolio Review
Microsoft shares underperformed due to concerns about its relationship with OpenAI following the Oracle/OpenAI deal announcement. Vertex Pharmaceuticals lost value following disappointing clinical tri...
Vertex's gene therapy shows promise in younger children with blood disorders
Vertex Pharmaceuticals said on Saturday its gene therapy helped children aged between 5 and 11 years with sickle cell disease to be free of painful events and allowed those with another blood disorder...
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in peo...
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Vertex to Participate in the Citi's 2025 Global Healthcare Conference on December 3
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in Citi's 2025 Global Healthcare Conference. Charlie Wagner, Chief Operating and Fi...
Columbia Contrarian Core Fund Q3 2025 Performance Review
The fund underperformed its benchmark, the Russell 1000 Index, during the third quarter. Videogame producer Electronic Art's was the top contributor during the period. Elevance Health was the top unde...